Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06257290

The Role of Platelet TLRs in Platelet Activation During VTE

Status
Recruiting
Phase
Study type
Observational
Enrollment
100 (estimated)
Sponsor
Centre Hospitalier Universitaire de Saint Etienne · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Venous thromboembolic disease (VTE) is a frequent and potentially serious pathology. Therapeutic management has improved considerably over the last few decades, enabling the application of codified management in line with the recently updated French management recommendations. One of the main remaining difficulties concerns VTE sequelae, mainly post-thrombotic syndrome after deep vein thrombosis, and post-pulmonary embolism syndrome after pulmonary embolism. The mechanisms leading to the absence of complete repermeabilization of vessels affected by Venous thromboembolic disease (VTE) are still poorly understood. The concept of immunothrombosis, closely associating immunity, inflammation and thrombosis, could (in part) explain the appearance of these sequelae. Platelets appear to play a key role in the onset of sequelae: Platelets are known to be involved both in the onset of a VTE episode and in the inflammatory response. This involvement is illustrated by the expression of inflammatory receptors such as TLR (toll-like receptor) 2 and TLR4. Th aim to investigate the role of platelets in the occurrence of sequelae, mainly via their role in the inflammatory response, in Venous thromboembolic disease (VTE) patients.

Conditions

Interventions

TypeNameDescription
BIOLOGICALblood sampleat Day 1 - date of patient inclusion at time of VTE diagnosis
BIOLOGICALblood sampleat 6 months (in the patient follow-up)

Timeline

Start date
2023-10-11
Primary completion
2025-12-01
Completion
2026-06-01
First posted
2024-02-13
Last updated
2025-03-18

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT06257290. Inclusion in this directory is not an endorsement.